News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dignity Sciences Release: DS107E-02 - Positive Phase 2 Results In Atopic Dermatitis



7/8/2014 6:13:43 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

DUBLIN, Ireland, July 8, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Dignity Sciences Limited, a privately held biopharmaceutical company, today announced positive Phase II results for DS107E (DGLA cream), as a topical treatment for atopic dermatitis.

This study was a randomized, placebo-controlled, double-blind, multi-centre Phase II study to investigate the efficacy and safety of topically applied DS107E (DGLA cream) and the dose-response of three doses (0.1%, 1%, 5%) of DS107E and placebo in patients who have mild or moderate atopic dermatitis.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES